| Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. | |
| | |
MedLine Citation:
|
PMID: 19266566 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The efficacy of infliximab for endoscopic recurrence after resection of Crohn's disease (CD) has not yet been reported. The aim of this prospective study was to investigate the impact of infliximab on early endoscopic lesions after resection for CD. METHODS: Twenty-six patients maintaining clinical remission (CD activity index [CDAI] score <150) with mesalamine (3 g/day) after resection showed endoscopic recurrence in the neoterminal ileum at 6 months postoperatively (=baseline). Over the following 6 months, 10 patients were treated with continuous mesalamine (3 g/day), 8 patients were treated with azathioprine therapy (50 mg/day), and the other 8 patients were treated with infliximab therapy (5 mg/kg, every 8 weeks). During ileocolonoscopy at baseline and 6 months later, mucosal biopsies were taken for cytokine assays. RESULTS: During 6-month observation, no patients in the infliximab group, 3 (38%) in the azathioprine group, and 7 (70%) in the mesalamine group developed clinical recurrence (CDAI >or=150) (P = 0.01). At 6 months, endoscopic inflammation was improved in 75% of patients in the infliximab group, 38% in the azathioprine group, and 0% in the mesalamine group (P = 0.006). The mucosal interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha levels significantly decreased in the infliximab group, while they significantly increased in the mesalamine group, and they did not change significantly in the azathioprine group. CONCLUSIONS: Infliximab therapy showed clear suppressive effects on clinical and endoscopic disease activity, and mucosal cytokine production in patients with early endoscopic lesions after resection. To confirm our conclusions, randomized controlled trials with a larger number of patients are necessary. |
| | |
Authors:
|
Takayuki Yamamoto; Satoru Umegae; Koichi Matsumoto |
Related Documents
:
|
23504186 - A novel methodology for av and vv delay optimization in crt: results from a randomized ... 21151676 - Management of dysfunctional uterine bleeding based on endometrial thickness. 14984376 - Combining infliximab and methotrexate in fistulizing crohn's disease resistant or intol... 23553506 - Comparative review of the safety and efficacy of ferric carboxymaltose versus standard ... 12582776 - Current status of an antireflux procedure in laparoscopic heller myotomy. 11777726 - Postoperative management and follow-up after corneal flap loss following laser in situ ... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article |
Journal Detail:
|
Title: Inflammatory bowel diseases Volume: 15 ISSN: 1536-4844 ISO Abbreviation: Inflamm. Bowel Dis. Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-09-21 Completed Date: 2009-12-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9508162 Medline TA: Inflamm Bowel Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 1460-6 Citation Subset: IM |
Affiliation:
|
Inflammatory Bowel Disease Center & Department of Surgery, Yokkaichi Social Insurance Hospital, Yokkaichi, Mie, Japan. naotaka@sannet.ne.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Anti-Inflammatory Agents / therapeutic use* Anti-Inflammatory Agents, Non-Steroidal / therapeutic use Antibodies, Monoclonal / therapeutic use* Azathioprine / therapeutic use Colonoscopy Crohn Disease / complications*, pathology, surgery* Enzyme-Linked Immunosorbent Assay Female Follow-Up Studies Humans Immunosuppressive Agents / therapeutic use Interleukin-1beta / metabolism Interleukin-6 / metabolism Male Mesalamine / therapeutic use Middle Aged Pilot Projects Postoperative Complications / drug therapy* Prognosis Prospective Studies Recurrence / prevention & control* Tumor Necrosis Factor-alpha / metabolism Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antibodies, Monoclonal; 0/Immunosuppressive Agents; 0/Interleukin-1beta; 0/Interleukin-6; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 446-86-6/Azathioprine; 89-57-6/Mesalamine |
| Comments/Corrections | |
Comment In:
|
Inflamm Bowel Dis. 2009 Oct;15(10):1458-9
[PMID:
19462431
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
Next Document: Developmental origins of mosaic brain evolution: Morphometric analysis of the developing zebra finch...